0001801385-24-000011.txt : 20240301 0001801385-24-000011.hdr.sgml : 20240301 20240301202002 ACCESSION NUMBER: 0001801385-24-000011 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240228 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROMANO KATHRYN CENTRAL INDEX KEY: 0001801385 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 24712512 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Romano Kathryn DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821080209 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 4 1 wk-form4_1709342394.xml FORM 4 X0508 4 2024-02-28 0 0001711279 Krystal Biotech, Inc. KRYS 0001801385 ROMANO KATHRYN C/O KRYSTAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701 PITTSBURGH PA 15203 0 1 0 0 Chief Accounting Officer 1 Common Stock 2024-02-28 4 M 0 648 63.55 A 13584 D Common Stock 2024-02-28 4 S 0 648 162.7102 D 12936 D Common Stock 2024-02-28 4 M 0 900 63.55 A 13836 D Common Stock 2024-02-28 4 S 0 900 163.6756 D 12936 D Common Stock 2024-02-28 4 M 0 1429 63.55 A 14365 D Common Stock 2024-02-28 4 S 0 1429 164.8075 D 12936 D Common Stock 2024-02-28 4 M 0 300 63.55 A 13236 D Common Stock 2024-02-28 4 S 0 300 166.0633 D 12936 D Common Stock 2024-02-28 4 M 0 300 63.55 A 13236 D Common Stock 2024-02-28 4 S 0 300 167.85 D 12936 D Common Stock 2024-02-28 4 M 0 1216 63.55 A 14152 D Common Stock 2024-02-28 4 S 0 1216 169.0946 D 12936 D Common Stock 2024-02-28 4 M 0 117 63.55 A 13053 D Common Stock 2024-02-28 4 S 0 117 169.8205 D 12936 D Common Stock 2024-02-28 4 M 0 90 63.55 A 13026 D Common Stock 2024-02-28 4 S 0 90 172.23 D 12936 D Common Stock 2024-02-28 4 M 0 5000 0 A 17936 D Common Stock 2024-02-28 4 F 0 2314 163.08 D 15622 D Stock Option (Right to Buy) 63.55 2024-02-28 2024-02-28 4 M 0 5000 0 D 2032-02-28 Common Stock 5000 25000 D Performance Stock Units 2024-02-28 2024-02-28 4 M 0 5000 0 D Common Stock 5000 5000 D Performance Stock Units 2024-02-29 4 A 0 15000 0 A Common Stock 15000 15000 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. The transaction was executed in multiple trades ranging from $162.155 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $163.190 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $164.300 to $165.220. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $165.980 to $166.110. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from$167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $168.680 to $169.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $169.790 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2024. The closing price on February 28, 2024 of the Company's common stock on NASDAQ. 50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024. The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024. Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting. If any applicable portion of the performance criteria have been achieved, the PSU award shall vest in two equal annual installments (February 28, 2025 and February 28, 2026). If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited. /s/ Kathryn Romano 2024-03-01